Hilltop Partners’s ResMed RMD Stock Holding History

Hilltop Partners’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-4,226	Closed	-$727K	–	104
2023 Q4	$727K	Sell	4,226 -1,547	-27%	-$238K	0.29%	50
2023 Q3	$854K	Buy	5,773 +2,935	+103%	+$531K	0.36%	46
2023 Q2	$620K	Buy	+2,838	New	+$633K	0.26%	54

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Hilltop Partners's RMD Position: Q1 2024 in Review

Hilltop Partners sold out of ResMed (RMD) in Q1 2024, closing a stake of 4,226 shares — an estimated $727K sold.

Hilltop Partners first reported a position in RMD in Q2 2023 and held it in 3 quarters. The position peaked at $854K in Q3 2023. 718 funds tracked by Wall St. Rank hold RMD as of Q1 2024.

Hilltop Partners reported no remaining ResMed position as of Q1 2024 after selling out during the quarter.
Hilltop Partners sold 4,226 ResMed shares in Q1 2024, an estimated $727K.
Hilltop Partners first reported a position in ResMed in Q2 2023 and held it in 3 quarters.
Hilltop Partners's ResMed position peaked at $854K in Q3 2023.
718 funds tracked by Wall St. Rank held ResMed as of Q1 2024.

Based on Hilltop Partners's 13F filing for Q1 2024, filed 13 May 2024.